Elicio Therapeutics (ELTX) Other Non-Current Liabilities (2022 - 2026)
Elicio Therapeutics' (ELTX) quarterly Other Non-Current Liabilities came in at $3.6 million in Q1 2026, up 21.51% YoY from $3.0 million in Q1 2025, and up 37.63% on a QoQ basis from $2.6 million in Q4 2025.
Elicio Therapeutics (ELTX) Other Non-Current Liabilities (2022 - 2026) Analysis & Trends
Elicio Therapeutics (ELTX) has 5 years of Other Non-Current Liabilities data on file, last reported at $3.6 million in Q1 2026.
- Quarterly Other Non-Current Liabilities rose 21.51% year-over-year to $3.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.6 million (up 21.51% YoY) and the FY2025 annual result came in at $2.6 million, down 7.53% from the prior year.
- Other Non-Current Liabilities rose to $3.6 million in Q1 2026, from $2.6 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $23.2 million in Q3 2024 to a low of $11000.0 in Q4 2023.
- A 5-year average of $4.3 million and a median of $2.9 million in 2024 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2024 — Other Non-Current Liabilities soared 25609.09% — and 2025, when it slumped 85.89%.
- Tracing ELTX's Other Non-Current Liabilities over 5 years: stood at $81000.0 in 2022, then slumped by 86.42% to $11000.0 in 2023, then soared by 25609.09% to $2.8 million in 2024, then dropped by 7.53% to $2.6 million in 2025, then surged by 37.63% to $3.6 million in 2026.
- The last three Other Non-Current Liabilities figures came in at $3.6 million (Q1 2026), $2.6 million (Q4 2025), and $3.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Elicio Therapeutics | 58.41 Mn | 34.91 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.12 Mn |
| Mar 31, 2026 | 3.60 Mn |
| Dec 31, 2025 | 2.62 Mn |
| Sep 30, 2025 | 3.88 Mn |
| Jun 30, 2025 | 600,000.00 |
| Mar 31, 2025 | 2.96 Mn |
| Dec 31, 2024 | 2.83 Mn |
| Sep 30, 2024 | 23.18 Mn |
| Jun 30, 2024 | 4.25 Mn |
| Mar 31, 2024 | 7.87 Mn |
| Dec 31, 2023 | 11,000.00 |
| Jun 30, 2022 | 81,000.00 |
| Mar 31, 2022 | 220,000.00 |